Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.
When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference?